BreachRx vs Solgari: Revenue, Funding & Team Size Compared
BreachRx generates $1.7M in revenue; Solgari generates $1.7M. BreachRx and Solgari are close to the same size by revenue. The table below compares BreachRx and Solgari on funding, valuation, customers, team size and headquarters — every figure GetLatka has verified for each company.
| Company | ||
|---|---|---|
| Revenue | $1.7M | $1.7M |
| Valuation | $13.7M | $17M |
| Team size | 25 | 30 |
| Founded | 2018 | 2012 |
| HQ | United States | Dublin, Ireland |
Want the full dataset? GetLatka tracks revenue, funding and team history for thousands of SaaS companies, with charts, growth rates and founder interviews.
BreachRx at a glance
BreachRx generates $1.7M in revenue with 25 employees, headquartered in United States.
- Revenue
- $1.7M
- Valuation
- $13.7M
- Team size
- 25
- Founded
- 2018
BreachRx is a SaaS platform that automatically generates tailored breach response plans in the aftermath of a data breach. We do not defend against data breaches; we use a technology-first approach to help companies recover from a breach…
Solgari at a glance
Solgari generates $1.7M in revenue with 30 employees, headquartered in Dublin, Ireland.
- Revenue
- $1.7M
- Valuation
- $17M
- Team size
- 30
- Founded
- 2012
Provider of Compliant & Integrated Omni-Channel Cloud Communication Services designed to transform global business communications. The company's Compliant & Integrated Omni-Channel Cloud Communication Services provides all the digital…
Other BreachRx alternatives
BreachRx competes with more than the companies on this page. Browse the full alternative lists to compare revenue, funding and team size across the category.
BreachRx vs Solgari: frequently asked questions
Is BreachRx or Solgari bigger?
BreachRx is the bigger company by revenue, at $1.7M against $1.7M for Solgari.
How much revenue does BreachRx make?
BreachRx generates $1.7M in annual revenue with a team of 25.
How much revenue does Solgari make?
Solgari generates $1.7M in annual revenue with a team of 30.